Deutsch English Français

Contact

EP1404871

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1404871

EP1404871 - METHOD FOR TREATMENT OF CANCER ASSOCIATED WITH ELEVATED HER 2 LEVELS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 18.12.2009 Database last updated on 06.11.2024
Most recent event Tooltip	18.12.2009	Application deemed to be withdrawn	published on 20.01.2010 [2010/03]
Applicant(s)	For all designated states Sloan Kettering Institute For Cancer Research 1275 York Avenue New York, NY 10021 / US
	[2004/15]
Inventor(s)	01 / ROSEN, Neal, c/o Office Of Industrial Affairs Memorial Sloan Kettering Cancer Ctr, 1275 York Av. New York, Ny New York 10021 / US
	02 / MUNSTER, Pamela, c/o H. lee Moffitt Cancer Center 12902 Magnolia Drive MRC 4072B Tampa, FL 33612 / US
	[2004/15]
Representative(s)	Murphy, Colm Damien, et al Ipulse 26 Mallinson Road London SW11 1BP / GB
	[N/P]
Former [2008/02]	Murphy, Colm Damien, et al Ipulse 5th floor 9-10 Savile Row London W1S 3PF / GB
Former [2007/12]	Murphy, Colm Damien, et al Urquhart-Dykes & Lord LLP 30 Welbeck Street London W1G 8ER / GB
Former [2004/15]	Salisbury, Clare Rachel Urquhart-Dykes & Lord, Alexandra House, 1 Alexandra Road Swansea, West Glamorgan SA1 5ED / GB
Application number, filing date	02737105.3	23.05.2002
	[2004/15]
	WO2002US16287
Priority number, date	US20010293246P	23.05.2001 Original published format: US 293246 P
	[2004/15]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO02094196
	Date:	28.11.2002
	Language:	EN
	[2002/48]
	Type:	A2 Application without search report
	No.:	EP1404871
	Date:	07.04.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 28.11.2002 takes the place of the publication of the European patent application.
	[2004/15]
Search report(s)	International search report - published on:	US	12.02.2004
	(Supplementary) European search report - dispatched on:	EP	01.09.2006
Classification	IPC:	C12Q1/68, C12P19/34, C07H21/04, C07K14/00, C07K16/00, A61K31/395, A61K31/336	[2006/26]
	CPC:	A61K31/395 (EP,US); A61K31/336 (EP,US); A61P35/00 (EP); A61P43/00 (EP)
	Former IPC [2004/15]	C12Q1/68, C12P19/34, C07H21/04, C07K14/00, C07K16/00
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2004/15]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	METHODE ZUR BEHANDLUNG VON KREBS IM ZUSAMMENHANG MIT ERHÖHTEN HER 2 WERTEN	[2004/15]
	English:	METHOD FOR TREATMENT OF CANCER ASSOCIATED WITH ELEVATED HER 2 LEVELS	[2004/15]
	French:	METHODE DE TRAITEMENT DE CANCERS ASSOCIES A DES NIVEAUX DE HER-2 ELEVES	[2004/15]
Entry into regional phase	25.11.2003	National basic fee paid
	25.11.2003	Search fee paid
	25.11.2003	Designation fee(s) paid
	25.11.2003	Examination fee paid
Examination procedure	12.12.2002	Request for preliminary examination filed International Preliminary Examining Authority: US
	25.11.2003	Examination requested [2004/15]
	18.02.2004	Amendment by applicant (claims and/or description)
	23.07.2007	Despatch of a communication from the examining division (Time limit: M04)
	27.11.2007	Reply to a communication from the examining division
	16.12.2008	Despatch of a communication from the examining division (Time limit: M06)
	27.06.2009	Application deemed to be withdrawn, date of legal effect [2010/03]
	20.08.2009	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2010/03]
Fees paid	Renewal fee
	05.04.2004	Renewal fee patent year 03
	07.05.2005	Renewal fee patent year 04
	20.05.2006	Renewal fee patent year 05
	28.04.2007	Renewal fee patent year 06
	22.05.2008	Renewal fee patent year 07
	Penalty fee
	Additional fee for renewal fee
	31.05.2009	08 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]US5932566 (SCHNUR RODNEY CAUGHREN [US], et al) [A] 1-3,17-20 * the whole document *;
		[Y]WO0061578 (SLOAN KETTERING INST CANCER [US], et al) [Y] 1-3,7-15,17-20 * the whole document *;
		[X] - ZHENG F F ET AL, "Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.", CANCER RESEARCH. 15 APR 2000, (20000415), vol. 60, no. 8, ISSN 0008-5472, pages 2090 - 2094, XP002381978 [X] 1-3,8-15,17-20 * the whole document, especially Table 1 page 2091; page 2064 left column paragraphs 4-5 *
		[X] - HARTMANN F ET AL, "Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 17 JAN 1997, (19970117), vol. 70, no. 2, ISSN 0020-7136, pages 221 - 229, XP002381979 [X] 1-3,8-15,17-20 * abstract * * page 221, column R, paragraph L * * page 222, column L, paragraph 1 * * page 225 - page 226, column R, paragraph 1 * * figure 8 * * page 228, column L * DOI: http://dx.doi.org/10.1002/(SICI)1097-0215(19970117)70:2<221::AID-IJC14>3.0.CO;2-L
		[X] - SCHULTE T W ET AL, "THE BENZOQUINONE ANSAMYCIN 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN BINDS TO HSP90 AND SHARES IMPORTANT BIOLOGIC ACTIVITIES WITH GELDANAMYCIN", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, (1998), vol. 42, ISSN 0344-5704, pages 273 - 279, XP002949121 [X] 1-3,7,10-15,17-20 * the whole document, especially page 273; page 274 left column second paragraph and right column third paragraph; page 276 right column paragraphs 2-4 * DOI: http://dx.doi.org/10.1007/s002800050817
		[Y] - AN W G ET AL, "DEPLETION OF P185ERBB2, RAF-1 AND MUTANT P53 PROTEINS BY GELDANAMYCIN DERIVATIVES CORRELATES WITH ANTIPROLIFERATIVE ACTIVITY", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, (1997), vol. 40, no. 1, ISSN 0344-5704, pages 60 - 64, XP001153415 [Y] 1-3,7-15,17-20 * the whole document * DOI: http://dx.doi.org/10.1007/s002800050626
		[Y] - SUPKO J G ET AL, "Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.", CANCER CHEMOTHERAPY AND PHARMACOLOGY. 1995, (1995), vol. 36, no. 4, ISSN 0344-5704, pages 305 - 315, XP008064559 [Y] 1-3,7-15,17-20 * page 305 - page 306, column L * * page 309 - page 310, column L, paragraph 1 * * page 312, column R, paragraph 1 * * page 313, column L, paragraph 1 * DOI: http://dx.doi.org/10.1007/BF00689048
		[A] - SCHNUR ET AL, "Inhibition of the Oncogene Product p185erb-b2 in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1995), vol. 38, no. 19, ISSN 0022-2623, pages 3806 - 3812, XP002202371 [A] 1-3,7-14,17-20 * the whole document * DOI: http://dx.doi.org/10.1021/jm00019a010
		[A] - SMITH D F ET AL, "Molecular chaperones. Biology and prospects for pharmacological intervention", PHARMACOLOGICAL REVIEWS 1998 UNITED STATES, (1998), vol. 50, no. 4, ISSN 0031-6997, pages 493 - 513, XP002381980 [A] 1-3,7-15,17-20 * from page 504 paragraph "C" to page 506 left column paragraph 3 * * page 506 right column paragraph "3" * * page 507 left column second paragraph *
		[A] - NECKERS L, "Effects of geldanamycin and other naturally occurring small molecule antagonists of heat shock protein 90 on HER2 protein expression", BREAST DISEASE, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, (2000), vol. 11, ISSN 0888-6008, pages 49 - 59, XP002961851 [A] 1-3,17-20 * abstract * * page 50 * * page 52, column R, paragraph 2 - page 53, column L * * summary on pages 56-57 *
		[PX] - SMITH V ET AL, "The effect of overexpression of C-ERBB2 on the chemosensitivity of a human ovarian carcinoma cell line", BRITISH JOURNAL OF CANCER, & MEETING OF THE BRITISH JOURNAL OF CANCER RESEARCH; LEEDS, UK; JULY 01-04, 2001, (200107), vol. 85, no. Supplement 1, ISSN 0007-0920, page 100, XP008064337 [PX] 1-3,8 * abstract *
	International search	[X]US5387584 (SCHNUR RODNEY C [US]);
		[X]US5932566 (SCHNUR RODNEY CAUGHREN [US], et al);
		[X]WO0061578 (SLOAN KETTERING INST CANCER [US], et al);
		[X] - CHAVANY ET AL., "p185 erbB2 binds to GRP94 in vivo", J. BIOL. CHEM., (19960301), vol. 271, no. 9, pages 4974 - 4977, XP002961850 DOI: http://dx.doi.org/10.1074/jbc.271.37.22796
		[X] - NECKERS L., "Effects of geldanamycin and other naturally occurring small molecule antagonists of heat shock protein 90 on HER2 protein expression", BREAST DISEASE, (2000), vol. 11, pages 49 - 59, XP002961851
		[X] - SCHNUR ET AL., "erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action and structure - activity relationships", J. MED. CHEM., (199509), vol. 38, pages 3813 - 3820, XP002193280 DOI: http://dx.doi.org/10.1021/jm00019a011

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p